Drug recall · October 15, 2025
Levothyroxine Sodium Tablets recall
Why: Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-450-15.
- Lots / codes
Lot # D2300045, Exp 12/31/2025.
- Quantity
- 54,432 bottles
- Company
- Accord Healthcare, Inc., Raleigh, NC
- Distribution
- Nationwide in the US
- Initiated
- September 16, 2025 · Voluntary: Firm initiated
- Classified
- October 6, 2025
- Reported
- October 15, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Levothyroxine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.